Source: EURLEX
Language: en
Format: md

|  |  |  |  |
| --- | --- | --- | --- |
| 12.10.2020 | EN | Official Journal of the European Union | C 339/32 |

---

Action brought on 27 August 2020 — Stada Arzneimittel v EUIPO — Pfizer (RUXIMBLIS)

(Case T-542/20)

(2020/C 339/40)

Language in which the application was lodged: German

Parties

Applicant: Stada Arzneimittel AG (Bad Vilbel, Germany) (represented by: J.-C. Plate and R. Kaase, lawyers)

Defendant: European Union Intellectual Property Office (EUIPO)

Other party to the proceedings before the Board of Appeal: Pfizer Inc. (New York, New York, United States)

Details of the proceedings before EUIPO

Applicant for the trade mark at issue: Applicant

Trade mark at issue: Application for EU word mark RUXIMBLIS — Application No. 17 865 738

Procedure before EUIPO: Opposition proceedings

Contested decision: Decision of the Fourth Board of Appeal of EUIPO of 16 June 2020 in Case R 1877/2019-4

Form of order sought

The applicant claims that the Court should:

|  |  |
| --- | --- |
| — | annul the contested decision; |

|  |  |
| --- | --- |
| — | order EUIPO to pay the costs, including the costs of the proceedings before the Board of Appeal. |

Plea in law

Infringement of Article 8(1)(b) of Regulation (EU) 2017/1001 of the European Parliament and of the Council.

---

[Top](#document1)